These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 25701366

  • 1. Lysophosphatidic acid receptor 1 antagonist ki16425 blunts abdominal and systemic inflammation in a mouse model of peritoneal sepsis.
    Zhao J, Wei J, Weathington N, Jacko AM, Huang H, Tsung A, Zhao Y.
    Transl Res; 2015 Jul; 166(1):80-8. PubMed ID: 25701366
    [Abstract] [Full Text] [Related]

  • 2. Lysophosphatidic acid receptor 1 modulates lipopolysaccharide-induced inflammation in alveolar epithelial cells and murine lungs.
    Zhao J, He D, Su Y, Berdyshev E, Chun J, Natarajan V, Zhao Y.
    Am J Physiol Lung Cell Mol Physiol; 2011 Oct; 301(4):L547-56. PubMed ID: 21821728
    [Abstract] [Full Text] [Related]

  • 3. Systemic blockade of LPA1/3 lysophosphatidic acid receptors by ki16425 modulates the effects of ethanol on the brain and behavior.
    Sánchez-Marín L, Ladrón de Guevara-Miranda D, Mañas-Padilla MC, Alén F, Moreno-Fernández RD, Díaz-Navarro C, Pérez-Del Palacio J, García-Fernández M, Pedraza C, Pavón FJ, Rodríguez de Fonseca F, Santín LJ, Serrano A, Castilla-Ortega E.
    Neuropharmacology; 2018 May 01; 133():189-201. PubMed ID: 29378212
    [Abstract] [Full Text] [Related]

  • 4. Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin.
    Ohashi T, Yamamoto T.
    Exp Dermatol; 2015 Sep 01; 24(9):698-702. PubMed ID: 25959255
    [Abstract] [Full Text] [Related]

  • 5. Activation of fibroblast-like synoviocytes derived from rheumatoid arthritis via lysophosphatidic acid-lysophosphatidic acid receptor 1 cascade.
    Miyabe Y, Miyabe C, Iwai Y, Yokoyama W, Sekine C, Sugimoto K, Harigai M, Miyasaka M, Miyasaka N, Nanki T.
    Arthritis Res Ther; 2014 Oct 02; 16(5):461. PubMed ID: 25273676
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of lysophosphatidic acid receptor ameliorates Sjögren's syndrome in NOD mice.
    Park E, Kim D, Lee SM, Jun HS.
    Oncotarget; 2017 Apr 18; 8(16):27240-27251. PubMed ID: 28460477
    [Abstract] [Full Text] [Related]

  • 7. Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis.
    Orosa B, García S, Martínez P, González A, Gómez-Reino JJ, Conde C.
    Ann Rheum Dis; 2014 Jan 18; 73(1):298-305. PubMed ID: 23486415
    [Abstract] [Full Text] [Related]

  • 8. Lysophosphatidylethanolamine utilizes LPA(1) and CD97 in MDA-MB-231 breast cancer cells.
    Park SJ, Lee KP, Kang S, Chung HY, Bae YS, Okajima F, Im DS.
    Cell Signal; 2013 Nov 18; 25(11):2147-54. PubMed ID: 23838008
    [Abstract] [Full Text] [Related]

  • 9. Blocking lysophosphatidic acid receptor 1 signaling inhibits diabetic nephropathy in db/db mice.
    Li HY, Oh YS, Choi JW, Jung JY, Jun HS.
    Kidney Int; 2017 Jun 18; 91(6):1362-1373. PubMed ID: 28111010
    [Abstract] [Full Text] [Related]

  • 10. Lysophosphatidic acid protects against acetaminophen-induced acute liver injury.
    Bae GH, Lee SK, Kim HS, Lee M, Lee HY, Bae YS.
    Exp Mol Med; 2017 Dec 08; 49(12):e407. PubMed ID: 29217823
    [Abstract] [Full Text] [Related]

  • 11. LPA receptor1 antagonists as anticancer agents suppress human lung tumours.
    Zhao PF, Wu S, Li Y, Bao G, Pei JY, Wang YW, Ma Q, Sun HJ, Damirin A.
    Eur J Pharmacol; 2020 Feb 05; 868():172886. PubMed ID: 31866407
    [Abstract] [Full Text] [Related]

  • 12. LPA1 receptor activation promotes renal interstitial fibrosis.
    Pradère JP, Klein J, Grès S, Guigné C, Neau E, Valet P, Calise D, Chun J, Bascands JL, Saulnier-Blache JS, Schanstra JP.
    J Am Soc Nephrol; 2007 Dec 05; 18(12):3110-8. PubMed ID: 18003779
    [Abstract] [Full Text] [Related]

  • 13. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors.
    Ohta H, Sato K, Murata N, Damirin A, Malchinkhuu E, Kon J, Kimura T, Tobo M, Yamazaki Y, Watanabe T, Yagi M, Sato M, Suzuki R, Murooka H, Sakai T, Nishitoba T, Im DS, Nochi H, Tamoto K, Tomura H, Okajima F.
    Mol Pharmacol; 2003 Oct 05; 64(4):994-1005. PubMed ID: 14500756
    [Abstract] [Full Text] [Related]

  • 14. Lysophosphatidic acid receptor1/3 antagonist inhibits the activation of satellite glial cells and reduces acute nociceptive responses.
    Hoshino Y, Okuno T, Saigusa D, Kano K, Yamamoto S, Shindou H, Aoki J, Uchida K, Yokomizo T, Ito N.
    FASEB J; 2022 Apr 05; 36(4):e22236. PubMed ID: 35218596
    [Abstract] [Full Text] [Related]

  • 15. CD14 is a key mediator of both lysophosphatidic acid and lipopolysaccharide induction of foam cell formation.
    An D, Hao F, Zhang F, Kong W, Chun J, Xu X, Cui MZ.
    J Biol Chem; 2017 Sep 01; 292(35):14391-14400. PubMed ID: 28705936
    [Abstract] [Full Text] [Related]

  • 16. Antidepressants activate the lysophosphatidic acid receptor LPA(1) to induce insulin-like growth factor-I receptor transactivation, stimulation of ERK1/2 signaling and cell proliferation in CHO-K1 fibroblasts.
    Olianas MC, Dedoni S, Onali P.
    Biochem Pharmacol; 2015 Jun 15; 95(4):311-23. PubMed ID: 25888927
    [Abstract] [Full Text] [Related]

  • 17. Both genetic deletion and pharmacological blockade of lysophosphatidic acid LPA1 receptor results in increased alcohol consumption.
    Castilla-Ortega E, Pavón FJ, Sánchez-Marín L, Estivill-Torrús G, Pedraza C, Blanco E, Suárez J, Santín L, Rodríguez de Fonseca F, Serrano A.
    Neuropharmacology; 2016 Apr 15; 103():92-103. PubMed ID: 26700247
    [Abstract] [Full Text] [Related]

  • 18. Lysophosphatidic acid as a mediator for proinflammatory agonists in a human corneal epithelial cell line.
    Zhang Z, Liu Z, Meier KE.
    Am J Physiol Cell Physiol; 2006 Nov 15; 291(5):C1089-98. PubMed ID: 16760261
    [Abstract] [Full Text] [Related]

  • 19. Lysophosphatidic acid-stimulated interleukin-6 and -8 synthesis through LPA1 receptors on human osteoblasts.
    Aki Y, Kondo A, Nakamura H, Togari A.
    Arch Oral Biol; 2008 Mar 15; 53(3):207-13. PubMed ID: 17915188
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of lysophosphatidic acid receptors 1 and 3 attenuates atherosclerosis development in LDL-receptor deficient mice.
    Kritikou E, van Puijvelde GH, van der Heijden T, van Santbrink PJ, Swart M, Schaftenaar FH, Kröner MJ, Kuiper J, Bot I.
    Sci Rep; 2016 Nov 24; 6():37585. PubMed ID: 27883026
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.